OurCrowd

OurCrowd Ltd. is a venture capital firm founded in 2013 and headquartered in Jerusalem, Israel, with additional offices in regions including the United States, the United Kingdom, and Asia-Pacific. Specializing in early-stage and growth investments, OurCrowd focuses on sectors such as transportation technology, greentech, fintech, medtech, cybersecurity, artificial intelligence, and digital health, among others. The firm aims to democratize venture capital by providing accredited investors access to curated, high-quality investment opportunities in emerging companies. OurCrowd conducts thorough vetting of potential investments and actively supports its portfolio companies by offering mentorship, recruiting industry advisors, and facilitating follow-on investment rounds. It is recognized as the most active venture investor in Israel and seeks to invest globally, particularly in urgent technological solutions responding to health emergencies and other societal needs. Through its extensive network, OurCrowd enhances growth opportunities for its portfolio companies throughout their lifecycle.

Denes Ban

Managing Director, Partner

Dan Bennett

Co-Founder and General Partner

Dean Berger

Associate

Morry Blumenfeld

Venture Partner

Guy Dassa

Senior Associate

Yori Nelken

General Partner

Moshe Raines

General Partner and Labs / 02 Managing Partner

Ron Stern

General Partner and Head of Portfolio

David Waimann

Venture Partner

Past deals in Image Recognition

D-ID

Series B in 2022
D-ID is a technology company that specializes in face recognition and de-identification solutions, catering to Fortune 500 companies and institutions globally. Founded in 2016 and based in Palo Alto, California, with an additional office in Tel Aviv, Israel, D-ID provides a suite of products designed to enhance identity protection and ensure compliance with regulations by eliminating sensitive biometric data from facial images. Their innovative technology can generate photos and videos that remain indistinguishable to the human eye while being unrecognizable to face recognition algorithms. This capability is crucial for organizations seeking to safeguard biometric databases and comply with privacy regulations. Additionally, D-ID leverages artificial intelligence to create personalized media for applications in e-learning, corporate training, and sales enablement, facilitating the development of AI-powered conversational agents and engaging video content.

Scopio

Venture Round in 2022
Scopio, LLC is an image search engine and licensing platform that focuses on trending images and videos from social media. Established in 2015 and headquartered in New York, the company utilizes artificial intelligence to facilitate the discovery and licensing of user-generated content. Its platform allows businesses, brands, non-governmental organizations, and live events to access a vast library of authentic and diverse photos, enabling them to customize messages and build their visual content libraries. Additionally, Scopio streamlines the copyright process for these images and videos, making it easier for users to search, license, publish, and analyze visual content sourced from social media.

SeeTrue

Series A in 2021
SeeTrue is an innovative company specializing in AI-based automatic threat detection for security screening processes. Founded in 2018 and headquartered in Tel Aviv, Israel, the company aims to enhance passenger journeys by making security screening faster, more accurate, and labor-free. Its technology employs artificial intelligence to automatically detect threats and resolve alarms, seamlessly integrating with existing X-ray and CT systems. This solution addresses various challenges related to security, passenger throughput, and operational costs, providing a significant improvement in the efficiency of security measures across diverse environments such as airports, mass transit systems, ports, critical infrastructure sites, stadiums, and office buildings. By leveraging its Autonomous AI Detection capabilities, SeeTrue adapts to the evolving landscape of potential threats, ultimately enabling clients to streamline operations and reduce labor costs.

RideVision

Series A in 2020
Ride Vision was created by technologists by day, motorbike riders by road, to give any motorcycle Predictive Vision. Ride Vision’s computer vision and neural network based CAT™ - Collision Aversion Technology leverages standard hardware and cameras to sense, predict and warn riders of threats on the road. Ride Vision can be incorporated into any new or traded motorbikes of any price range.

Sight Diagnostics

Series D in 2020
Sight Diagnostics Ltd. is a medical device company based in Tel Aviv, Israel, that focuses on developing advanced diagnostic solutions for blood diseases. Utilizing proprietary machine-vision technology, the company has created a platform that leverages artificial intelligence for blood analysis and infectious disease detection. Its flagship product, Parasight, is a malaria detection device that accurately identifies and enumerates malaria through a digital fluorescent microscopy process. Since its launch in 2014, Sight Diagnostics has sold over 600,000 tests across 25 countries. Additionally, the company has introduced OLO, a device that facilitates complete blood count testing at the point-of-care, which is currently available in the European Union and other non-US markets. By providing scalable and precise blood diagnostics, Sight Diagnostics aims to enhance patient outcomes and improve overall healthcare accessibility.

RealView

Series C in 2020
RealView Imaging Ltd. is an Israeli company that specializes in 3D holographic display and interface systems tailored for medical imaging applications. Founded in 2008 and based in Yokneam, the company has developed a proprietary technology that projects hyper-realistic, dynamic 3D holographic images that appear to float in the air, allowing users to interact with them without the need for eyewear or screens. This innovation enables medical professionals to engage with 3D images in a natural way, enhancing their ability to evaluate live holographic imaging in various clinical fields, including interventional cardiology, cardiac electrophysiology, structural heart disease interventions, interventional radiology, and complex surgical procedures. RealView's technology represents a significant advancement in digital holography and real-time 3D interaction.

Autobrains

Series B in 2019
Cartica’s revolutionary automotive visual intelligence platform is built on the foundation of a mature self-learning technology backed by more than 200 patents. Utilizing robust signature-based representation structures coupled with unsupervised learning methodologies, Cartica’s visual intelligence platform garners a comprehensive and detailed understanding of the vehicle’s environment.

MultiVu

Seed Round in 2019
MultiVu Technologies, Ltd. is a company based in Tel Aviv, Israel, that specializes in 3D imaging solutions focused on face authentication. The firm has developed a patented light field technology that utilizes a single lens camera to enhance biometric security while ensuring eye safety and power efficiency. This innovative solution allows for quick, three-dimensional snapshots in various lighting conditions, making it suitable for both mobile and stationary devices without the need for additional hardware. By combining face and depth recognition with deep learning algorithms, MultiVu aims to provide a cost-effective alternative to leading brands in the biometric authentication market.

Brodmann17

Series A in 2019
Brodmann17 Ltd is an Israeli company established in 2016, specializing in computer vision technology aimed at enhancing safety in mobility through vision-AI. The company's innovative architecture utilizes deep learning neural networks to perform tasks such as pedestrian and face detection in real-time. Brodmann17's software is designed to operate efficiently on small devices and commodity CPU environments, achieving high accuracy while requiring minimal computational power. This capability allows their technology to meet the stringent standards of the automotive industry, enabling improved automated driving systems. The company collaborates with various global original equipment manufacturers and Tier-1 suppliers to address diverse automotive use cases, ultimately promoting accessible smart mobility solutions. Headquartered in Hod Hasharon, Israel, Brodmann17 is led by experienced technologists and researchers.

Sight Diagnostics

Series C in 2019
Sight Diagnostics Ltd. is a medical device company based in Tel Aviv, Israel, that focuses on developing advanced diagnostic solutions for blood diseases. Utilizing proprietary machine-vision technology, the company has created a platform that leverages artificial intelligence for blood analysis and infectious disease detection. Its flagship product, Parasight, is a malaria detection device that accurately identifies and enumerates malaria through a digital fluorescent microscopy process. Since its launch in 2014, Sight Diagnostics has sold over 600,000 tests across 25 countries. Additionally, the company has introduced OLO, a device that facilitates complete blood count testing at the point-of-care, which is currently available in the European Union and other non-US markets. By providing scalable and precise blood diagnostics, Sight Diagnostics aims to enhance patient outcomes and improve overall healthcare accessibility.

Vayavision

Seed Round in 2018
VayaVision Sensing Ltd. is a technology company that specializes in developing perception engine software aimed at enhancing the safety and efficiency of autonomous driving. Founded in 2016 and headquartered in Or Yehuda, Israel, the company offers VAYA-Drive, an artificial intelligence cognition platform that integrates raw data fusion with advanced computer vision techniques. This platform generates comprehensive environmental models, enabling critical functions such as road and free space detection, lane detection, object detection and tracking, and recognition of traffic signs. By utilizing deep learning algorithms, VayaVision delivers a reliable detection and classification system that accurately assesses the size, shape, and velocity of surrounding objects, including small obstacles. This innovative approach not only improves sensing capabilities for autonomous vehicles but also contributes to cost reductions within the automotive industry. Since July 2020, VayaVision has operated as a subsidiary of LeddarTech Inc.

Zebra Medical Vision

Venture Round in 2018
Zebra Medical Vision Ltd. is an Israeli company founded in 2014 that specializes in developing an imaging analytics platform aimed at enhancing healthcare delivery. The platform provides a comprehensive suite of imaging research solutions for clinicians, advanced machine learning and computer vision diagnostic algorithms for developers, and risk management tools for healthcare providers. By offering access to a vast repository of anonymized clinical records, Zebra Medical Vision supports researchers in accelerating the development of decision support tools and improving diagnostic accuracy. The company collaborates with various partners, including USARAD Holdings and TELUS Ventures, to leverage its network of over 1,100 hospitals and healthcare providers. This collaboration fosters innovation and enhances patient care through the application of advanced analytics and automated clinical insights, positioning Zebra Medical Vision as a leader in the integration of AI and machine learning in medical imaging.

Zebra Medical Vision

Series C in 2018
Zebra Medical Vision Ltd. is an Israeli company founded in 2014 that specializes in developing an imaging analytics platform aimed at enhancing healthcare delivery. The platform provides a comprehensive suite of imaging research solutions for clinicians, advanced machine learning and computer vision diagnostic algorithms for developers, and risk management tools for healthcare providers. By offering access to a vast repository of anonymized clinical records, Zebra Medical Vision supports researchers in accelerating the development of decision support tools and improving diagnostic accuracy. The company collaborates with various partners, including USARAD Holdings and TELUS Ventures, to leverage its network of over 1,100 hospitals and healthcare providers. This collaboration fosters innovation and enhances patient care through the application of advanced analytics and automated clinical insights, positioning Zebra Medical Vision as a leader in the integration of AI and machine learning in medical imaging.

Unispectral

Series A in 2018
Unispectral, founded in 2016 and headquartered in Tel Aviv, Israel, specializes in developing advanced camera sensors that utilize hyperspectral imaging technology. This innovative approach leverages MEMS technology to analyze the material properties of solids, liquids, and gases, allowing for enhanced imaging capabilities, including low-light performance and rich color photography. The company's platform captures megapixel images while simultaneously gathering spectral data for each object in the frame. By integrating standard object recognition, image processing, deep learning tools, and spectral analysis, Unispectral's products enable clients to significantly improve image quality, especially in challenging lighting conditions.

Sight Diagnostics

Series B in 2016
Sight Diagnostics Ltd. is a medical device company based in Tel Aviv, Israel, that focuses on developing advanced diagnostic solutions for blood diseases. Utilizing proprietary machine-vision technology, the company has created a platform that leverages artificial intelligence for blood analysis and infectious disease detection. Its flagship product, Parasight, is a malaria detection device that accurately identifies and enumerates malaria through a digital fluorescent microscopy process. Since its launch in 2014, Sight Diagnostics has sold over 600,000 tests across 25 countries. Additionally, the company has introduced OLO, a device that facilitates complete blood count testing at the point-of-care, which is currently available in the European Union and other non-US markets. By providing scalable and precise blood diagnostics, Sight Diagnostics aims to enhance patient outcomes and improve overall healthcare accessibility.

Zebra Medical Vision

Series B in 2016
Zebra Medical Vision Ltd. is an Israeli company founded in 2014 that specializes in developing an imaging analytics platform aimed at enhancing healthcare delivery. The platform provides a comprehensive suite of imaging research solutions for clinicians, advanced machine learning and computer vision diagnostic algorithms for developers, and risk management tools for healthcare providers. By offering access to a vast repository of anonymized clinical records, Zebra Medical Vision supports researchers in accelerating the development of decision support tools and improving diagnostic accuracy. The company collaborates with various partners, including USARAD Holdings and TELUS Ventures, to leverage its network of over 1,100 hospitals and healthcare providers. This collaboration fosters innovation and enhances patient care through the application of advanced analytics and automated clinical insights, positioning Zebra Medical Vision as a leader in the integration of AI and machine learning in medical imaging.

Zebra Medical Vision

Series A in 2015
Zebra Medical Vision Ltd. is an Israeli company founded in 2014 that specializes in developing an imaging analytics platform aimed at enhancing healthcare delivery. The platform provides a comprehensive suite of imaging research solutions for clinicians, advanced machine learning and computer vision diagnostic algorithms for developers, and risk management tools for healthcare providers. By offering access to a vast repository of anonymized clinical records, Zebra Medical Vision supports researchers in accelerating the development of decision support tools and improving diagnostic accuracy. The company collaborates with various partners, including USARAD Holdings and TELUS Ventures, to leverage its network of over 1,100 hospitals and healthcare providers. This collaboration fosters innovation and enhances patient care through the application of advanced analytics and automated clinical insights, positioning Zebra Medical Vision as a leader in the integration of AI and machine learning in medical imaging.

Cimagine

Convertible Note in 2015
Cimagine Media Ltd. provides a Software-as-a-Service based AR commerce platform for retailers and brands. Its cloud-based mobile platform used for the instant visualization of items of interest over their intended locations in realistic 3D. The company’s platform augments e-commerce and m-commerce to help retailers in enhancing the shopping experience by letting consumers engage with products in their homes; and allows end users to access products via a Weblink, barcode, catalogs, advertisements, or other media sharing applications. Cimagine Media Ltd. was incorporated in 2012 and is based in Yokneam Ilit, Israel. As of December 31, 2016, Cimagine Media Ltd. operates as a subsidiary of Snap Inc.

Zebra Medical Vision

Seed Round in 2015
Zebra Medical Vision Ltd. is an Israeli company founded in 2014 that specializes in developing an imaging analytics platform aimed at enhancing healthcare delivery. The platform provides a comprehensive suite of imaging research solutions for clinicians, advanced machine learning and computer vision diagnostic algorithms for developers, and risk management tools for healthcare providers. By offering access to a vast repository of anonymized clinical records, Zebra Medical Vision supports researchers in accelerating the development of decision support tools and improving diagnostic accuracy. The company collaborates with various partners, including USARAD Holdings and TELUS Ventures, to leverage its network of over 1,100 hospitals and healthcare providers. This collaboration fosters innovation and enhances patient care through the application of advanced analytics and automated clinical insights, positioning Zebra Medical Vision as a leader in the integration of AI and machine learning in medical imaging.

Sight Diagnostics

Series A in 2014
Sight Diagnostics Ltd. is a medical device company based in Tel Aviv, Israel, that focuses on developing advanced diagnostic solutions for blood diseases. Utilizing proprietary machine-vision technology, the company has created a platform that leverages artificial intelligence for blood analysis and infectious disease detection. Its flagship product, Parasight, is a malaria detection device that accurately identifies and enumerates malaria through a digital fluorescent microscopy process. Since its launch in 2014, Sight Diagnostics has sold over 600,000 tests across 25 countries. Additionally, the company has introduced OLO, a device that facilitates complete blood count testing at the point-of-care, which is currently available in the European Union and other non-US markets. By providing scalable and precise blood diagnostics, Sight Diagnostics aims to enhance patient outcomes and improve overall healthcare accessibility.

Sight Diagnostics

Seed Round in 2011
Sight Diagnostics Ltd. is a medical device company based in Tel Aviv, Israel, that focuses on developing advanced diagnostic solutions for blood diseases. Utilizing proprietary machine-vision technology, the company has created a platform that leverages artificial intelligence for blood analysis and infectious disease detection. Its flagship product, Parasight, is a malaria detection device that accurately identifies and enumerates malaria through a digital fluorescent microscopy process. Since its launch in 2014, Sight Diagnostics has sold over 600,000 tests across 25 countries. Additionally, the company has introduced OLO, a device that facilitates complete blood count testing at the point-of-care, which is currently available in the European Union and other non-US markets. By providing scalable and precise blood diagnostics, Sight Diagnostics aims to enhance patient outcomes and improve overall healthcare accessibility.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.